Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition and application thereof in treating acute myelitis

A composition and a technique for myelitis, applied in the field of medicine, can solve the problems of large side effects, unsatisfactory effect, long medication time, etc., and achieve the effects of promoting the generation of neurotransmitters, enhancing the immunity of the body, and recovering the cell function.

Inactive Publication Date: 2017-01-18
杨延芳
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the past, conventional doses of corticosteroids had unsatisfactory therapeutic effects. The medication took a long time, and the effect was slow, the effect was not good, and the side effects were relatively large.
In recent years, it has been reported that high-dose methylprednisolone pulse therapy has achieved good results in the treatment of multiple sclerosis, Guillain-Barré syndrome, myasthenia gravis and other nervous system immune diseases. The treatment of acute myelitis is still controversial at home and abroad, and the related research is not very exhaustive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Calculated by weight, the pharmaceutical composition comprises 15 parts of notoginsenoside R1, 5 parts of naringin, 9 parts of salicin and 1 part of α-pinene.

Embodiment 2

[0014] Calculated by weight, the pharmaceutical composition comprises 16 parts of notoginsenoside R1, 6 parts of naringin, 11 parts of salicin and 2 parts of α-pinene.

Embodiment 3

[0016] Calculated by weight, the pharmaceutical composition comprises 10 parts of notoginsenoside R1, 4 parts of naringin, 8 parts of salicin and 6 parts of α-pinene.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition and application thereof in treating acute myelitis. The pharmaceutical composition is prepared from, by weight, 14-16 parts of notoginsenoside R1, 5-6 parts of naringin, 9-11 parts of salicin and 1-2 parts of alpha-pinene, when the raw materials are matched, the pharmaceutical composition has an excellent treatment effect on acute myelitis.

Description

technical field [0001] The invention relates to a pharmaceutical composition and its application in treating acute myelitis, belonging to the technical field of medicine. Background technique [0002] Acute myelitis is an autoimmune disease induced by non-specific infection, and it is a relatively low incidence but serious spinal cord disease. It can involve the entire spinal cord, but is most common in the thoracic spinal cord. The texture of the affected spinal cord became soft and the pia mater was congested with the naked eye. On the cut surface, the boundary between the gray matter and white matter of the spinal cord was unclear, myelomalacia, and spotting. Its incidence rate is about 0.1 to 0.4 / 100,000, and it can occur in all age groups. No gender and familial differences. The disease usually has an acute onset, and the first symptoms are mostly numbness and weakness of the lower limbs, pain in the neck and back, and a sense of girdle in the corresponding parts. I...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P25/00A61P37/02A61K31/015A61K31/7034A61K31/704
CPCA61K31/704A61K31/015A61K31/7034A61K31/7048A61K2300/00
Inventor 杨延芳
Owner 杨延芳
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products